Drug Discovery & DDS– category –
-
Eli Lilly’s Oral GLP-1 Agonist Orforglipron Shows Promising Weight Loss and Safety in Phase 2 Trials, Rivaling Injectables
Endocrinology Today USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, demonstrated weight loss comparable to some injectable GLP-1s in Phase 2 trials for obesity and type 2 diabetes. As a non-peptide sma... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
Waterfall Scientific Wins Up to $54.5 Million from ARPA-H to Pioneer Continuous-Flow mRNA Manufacturing Platform
Pulse 2.0 USA Overview Waterfall Scientific has been awarded up to $54.5 million from ARPA-H to lead a consortium in developing the ESCALATOR project, a continuous-flow platform for mRNA manufacturing and characterization. This initiativ... -
Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease
Fierce Pharma USA Overview Ionis Pharmaceuticals has received FDA approval for Zanvastro (zilganersen), an antisense oligonucleotide (ASO) therapy, as the first disease-modifying treatment for Alexander disease. Zanvastro operates by spe... -
Catalent Secures $4.1B Refinancing, Fuels Major Expansion in Biologics and Oral Drug Manufacturing to Meet GLP-1 Demand
Pharmaceutical Technology USA Overview Catalent successfully completed a $4.1 billion debt refinancing, earmarking substantial capital for expanding its biologics and oral drug manufacturing capacity. These strategic investments, includi... -
Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications
Facebook (Vaxcyte, Vivaldi Biosciences) USA Overview Moderna's RSV vaccine mRESVIA® gained FDA approval following Breakthrough Therapy Designation, reaffirming the power of mRNA technology in infectious disease prevention. Concurrently, ... -
The Pharma AI Data Problem: Complex Clinical Trial Data Impedes AI Model Development and Deployment
ACI Infotech USA Overview Despite significant investments in AI within the pharmaceutical sector, the structural complexity and inconsistency of clinical trial data present a major 'clinical trial data problem,' hindering the effective d... -
Recorna and Starna Therapeutics Partner to Advance RNA Gene Editing for Lung Diseases Leveraging STAR LNP Technology
Insight, China's Pharmaceutical Industry China Overview Chinese firms Recorna Biotechnology and Starna Therapeutics have formed a strategic partnership to develop RNA gene editing therapeutics for lung diseases. The collaboration will le... -
Insitro Appoints Hideo Makimura as Chief Medical Officer to Accelerate Transition from AI Drug Discovery to Clinical-Stage Company
BioSpace USA Overview Insitro, a pioneer in AI drug discovery, announced the appointment of Hideo Makimura as Chief Medical Officer (CMO), signaling a strategic acceleration from an AI-driven discovery firm to a clinical-stage company. M... -
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr...
